Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
Copyright 2025 The Associated Press. All Rights Reserved. A sign for Eli Lilly & Co. appears outside their corporate ...
Shares of Eli Lilly & Co. LLY slid 3.00% to $844.27 Friday, on what proved to be an all-around grim trading session for the ...
it’s about as confident tone as you can expect from or as you’d want from a management team,” said Kevin Gade, chief operating officer at Bahl & Gaynor, which owns Lilly’s shares.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results